Longer Term Data Confirm Subcutaneous Rituximab Efficacy in Follicular Lymphoma

News
Video
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

In this video we discuss longer term results of the phase III SABRINA study, which tested the safety and efficacy of subcutaneous rituximab in patients with follicular lymphoma.

The availability of subcutaneous rituximab, which takes less than 10 minutes to administer, offers convenience for both patients and healthcare professionals compared with rituximab delivered intravenously.

Longer term safety and efficacy data (median follow-up = 37 months) from the phase III SABRINA study, which examined subcutaneous rituximab in treatment-naive follicular lymphoma patients, were presented at the 2016 American Society of Hematology (ASH) Annual Meeting, held December 3–6 in San Diego, California.

In this video Andrew Davies, PhD, of the University of Southampton and Cancer Research UK, discusses the findings.

Recent Videos
No evidence indicates synergistic toxicity when combining radiation with CAR T-cell therapy in this population, according to Timothy Robinson, MD, PhD.
The addition of radiotherapy to CAR T-cell therapy may particularly benefit patients with localized disease, according to Timothy Robinson, MD, PhD.
Timothy Robinson, MD, PhD, discusses how radiation may play a role as bridging therapy to CAR T-cell therapy for patients with relapsed/refractory DLBCL.
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Carla Casulo, MD, with the Oncology Brothers presenting slides
Carla Casulo, MD, with the Oncology Brothers presenting slides
Carla Casulo, MD, with the Oncology Brothers presenting slides
Related Content
3 Things You Should Know About Biomarkers in DLBCL

3 Things You Should Know About Biomarkers in DLBCL

Matthew A. Lunning, MD;Sarah C. Rutherford, MD
November 11th 2024
Article

DLBCL is a genetically heterogeneous malignancy with multiple subtypes and recent investigations based on molecular profiles have opened the possibility for personalized therapy in this disease space.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Hematologic cell transplantation use rates have improved, although they still show disparities for minority groups such as non-Hispanic Black populations.

Disparities Remain in HCT Use Rates for Minority Groups Despite Growth

Tim Cortese
November 5th 2024
Article

Hematologic cell transplantation use rates have improved, although they still show disparities for minority groups such as non-Hispanic Black populations.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Rahul Banerjee, MD, FACP;Noopur Raje, MD
September 2nd 2024
Podcast

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Phase 3 data show that nivolumab/AVD may also reduce long-term toxicities vs brentuximab vedotin/AVD in advanced Hodgkin lymphoma.

Nivolumab Combo Improves PFS in Stage III/IV Advanced Hodgkin Lymphoma

Russ Conroy
October 17th 2024
Article

Phase 3 data show that nivolumab/AVD may also reduce long-term toxicities vs brentuximab vedotin/AVD in advanced Hodgkin lymphoma.

The FDA has set a Prescription Drug User Fee Act date in the first quarter of 2025 for the potential approval of acalabrutinib in previously untreated MCL.

Acalabrutinib Earns FDA Priority Review in Untreated Mantle Cell Lymphoma

Russ Conroy
October 3rd 2024
Article

The FDA has set a Prescription Drug User Fee Act date in the first quarter of 2025 for the potential approval of acalabrutinib in previously untreated MCL.